Literature DB >> 20935165

Do engineered natriuretic peptides have greater therapeutic potential than do native peptides?

Arthur H L From.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20935165      PMCID： PMC2972689          DOI： 10.1093/cvr/cvq319

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  12 in total

Review 1.  The role of NHE-1 in myocardial hypertrophy and remodelling.

Authors:  Morris Karmazyn; Ana Kilić; Sabzali Javadov
Journal:  J Mol Cell Cardiol       Date:  2008-02-09       Impact factor: 5.000

2.  A novel chimeric natriuretic peptide reduces cardiomyocyte hypertrophy through the NHE-1-calcineurin pathway.

Authors:  Ana Kilic; Venkatesh Rajapurohitam; Sharon M Sandberg; Asad Zeidan; J Craig Hunter; Nazo Said Faruq; Candace Y Lee; John C Burnett; Morris Karmazyn
Journal:  Cardiovasc Res       Date:  2010-08-02       Impact factor: 10.787

3.  Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice.

Authors:  Yong Wang; Monique C de Waard; Anja Sterner-Kock; Holger Stepan; Heinz-Peter Schultheiss; Dirk J Duncker; Thomas Walther
Journal:  Eur J Heart Fail       Date:  2007-04-03       Impact factor: 15.534

4.  Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP.

Authors:  Ondrej Lisy; Brenda K Huntley; Daniel J McCormick; Paul A Kurlansky; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2008-07-01       Impact factor: 24.094

5.  Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects.

Authors:  Candace Y W Lee; Horng H Chen; Ondrej Lisy; Suzanne Swan; Courtney Cannon; Hsiao D Lieu; John C Burnett
Journal:  J Clin Pharmacol       Date:  2009-04-24       Impact factor: 3.126

Review 6.  Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction.

Authors:  Shu Kasama; Mayumi Furuya; Takuji Toyama; Shuichi Ichikawa; Masahiko Kurabayashi
Journal:  Eur Heart J       Date:  2008-05-19       Impact factor: 29.983

7.  Normalization of the calcineurin pathway underlies the regression of hypertensive hypertrophy induced by Na+/H+ exchanger-1 (NHE-1) inhibition.

Authors:  Irene L Ennis; Carolina D Garciarena; Eduardo M Escudero; Néstor G Pérez; Raúl A Dulce; María C Camilión de Hurtado; Horacio E Cingolani
Journal:  Can J Physiol Pharmacol       Date:  2007 Mar-Apr       Impact factor: 2.273

8.  Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart.

Authors:  Deborah M Dickey; Darcy R Flora; Paula M Bryan; Xin Xu; Yingjie Chen; Lincoln R Potter
Journal:  Endocrinology       Date:  2007-04-05       Impact factor: 4.736

9.  Effect of long-term B-type natriuretic peptide treatment on left ventricular remodeling and function after myocardial infarction in rats.

Authors:  Jiangui He; Yili Chen; Yiyi Huang; Fengjuan Yao; Zhongkai Wu; Shenglong Chen; Lichun Wang; Pingxi Xiao; Gang Dai; Rongsen Meng; Chengxi Zhang; Lilong Tang; Yuli Huang; Zhiming Li
Journal:  Eur J Pharmacol       Date:  2008-11-12       Impact factor: 4.432

Review 10.  Impact of nesiritide on renal function and mortality in patients suffering from heart failure.

Authors:  Ioannis D Dontas; Theodoros Xanthos; Ismene Dontas; Pavlos Lelovas; Lila Papadimitriou
Journal:  Cardiovasc Drugs Ther       Date:  2009-06       Impact factor: 3.727
View more
  1 in total

1.  Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart.

Authors:  A van der Pol; M F Hoes; R A de Boer; P van der Meer
Journal:  J Intern Med       Date:  2020-06-17       Impact factor: 8.989
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.